Data integrity is key to the success of any cell therapy program. CDMOs can implement robust data management systems for ...

SAN DIEGO—Cytiva has launched its Sefia next-generation manufacturing platform, with the goal of helping drug developers and larger healthcare providers accelerate their production of chimeric antigen ...

Adoptive therapies based on CAR/TCR T cells—that is, T cells with an engineered chimeric antigen receptor (CAR) or a T-cell receptor (TCR)—have shown promise for a range of cancers, offering hope to ...

When most people think of cancer care, they rarely associate it with what goes on behind the scenes to create life-saving treatments. For starters, developing cell and gene therapies is pricey, and ...

Biotechnology company Bracco Imaging announced its expansion into the cell-therapy manufacturing space, establishing a new ...

Whether for drug screening or toxicity testing, stem cell-based 3D tissue models are key to biomedical research. However, ...

Cellares. Bristol Myers Squibb and Cellares Announce a $380M Worldwide Capacity Reservation and Supply Agreement for the Manufacture of CAR T Cell Therapies to Bring the Promise of Cell Therapy to ...

Cellares has joined forces with the Stanford Center for Definitive and Curative Medicine (CDCM) and Stanford Innovative ...

DUBLIN--(BUSINESS WIRE)--The "Point-of-Care Cell and Gene Therapy Manufacturing Market - A Global and Regional Analysis: Focus on Technology, Therapeutic Area, End User, and Regional Analysis - ...